Фолий кислотаси метаболизмининг бачадон бўйни касалликлари ривожланишидаги ўрни

Сухих Г.Т., Прилепская В.Н., ред.Профилактика рака шейки матки: Руководство для врачей. 3-е изд. М.: МЕДпресс-информ; 2018. 192с.

Стерн П.Л., Г.С.Китченер Г.С., ред. Вакцина для профилактики рака шейки матки: Пер. с англ.Сухих Г.Т., Прилепская В.Н., ред.М.: МЕДпресс-информ; 2019.192с

Роговская С.И. Папилломавирусная инфекция у женщин и патология шейки матки: в помощь практикующему врачу. 2-е изд. М.: ГЭОТАР-Медиа; 2018. 192с

Bleotu C., Botezatu A., Goia C.D., Socolov D., Corniţescu F., Teleman S. et al.P16ink4A-A possible marker in HPV persistence screening. Roum. Arch. Microbiol. Immunol. 2019; 68(3): 183–9. 5.Davey E., Barratt A., Irwig L., Chan S.F., Macaskill P., Mannes P., Saville A.M. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet. 2016; 376(9505): 122–32.

Franco E.L., Harper D.M. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine. 2015; 23(17–18): 2388–94.

Hutchcraft M. L. et al. Conization pathologic features as a predictor of intermediate and high-risk features on radical hysterectomy specimens in early-stage cervical cancer //Gynecologic oncology. – 2019. – Т. 153. – №. 2. – С. 255-258.

Muñoz N., Bosch F.X., Castellsagué X., Díaz M., de Sanjose S., Hammouda D. et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer. 2020; 111(2): 278–85.

Nuovo J., Melnikow J., Howell L.P. New tests for cervical cancer screening. Am. Fam. Physician. 2011; 64: L780–6. 10.Pierry D., Weiss G., Lack B., Chen V., Fusco J. Intracellular human papillomavirus E6, E7 mRNA quantification predicts CIN 2+ in cervical biopsies better than Papanicolaou screening for women regardless of age. Arch. Pathol. Lab. Med. 2012; 136(8): 956–60. 11. Ramirez P., Frumovitz M., Pareja R. et.al. Phase III randomized trial of laparoscopic or robotic radical hysterectomy vs. abdominal radical hysterectomy in patients with early-stage cervical cancer: LACC Trial. N Engl J Med 2018;379(20):1895–904. 12. Snijders P., van den Brule A., Meijer C. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J. Pathol. 2019; 201(1)

Kurman R.J., Carcangiu M.L., Harrington C.S. et al. (eds.) WHO Classification of Tumors of the Female Reproductive Organs. Geneva, Switzerland: WHO Press, 2018. World Health Organization Classification of Tumors. 4th edn. 8. NCCN guidelines panel. Cervical Cancer. Version 3.2019. Published online: https://www.nccn.org/professionals/physician_gls/pdf/cervical. 2018.

Webb J.C., Key C.R., Qualls C.R. et al. Population-based study of microinvasive adenocarcinoma of the uterine cervix. Obstet Gynecol 2018;97(5 Pt 1):701–6.